An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial
Open accessAbstract
Importance: Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy. Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) have been implicated in the pathobiology of AS. The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab reduces circulating LDL-C concentrations by 50% to 60% and Lp(a) by 20% to 30%. Objective: To determine whether evolocumab reduces the risk of AS events in patients with atherosclerotic cardiovascular disease. Interventions: Patients were randomized 1:1 to evolocumab or placebo. Design, Setting, and Participants: Exploratory analysis of the FOURIER trial, which enrolled 27 564 patients with stable atherosclerotic cardiovascular disease who were taking statin therapy at 1242 sites in 49 countries from February 2013 to November 2016. Patients were randomized to evolocumab or placebo and followed up for a median (interquartile range) of 2.2 (1.8-2.5) years. This post hoc analysis was performed from September 2019 to February 2020. Main Outcomes and Measures: Site-reported adverse events of new or worsening AS or aortic valve replacement (termed AS events). The adjusted risk of AS events was calculated with a multivariable model including concentrations of Lp(a) and LDL-C corrected for Lp(a) content, plus age, sex, diabetes, hypertension, current smoking, and estimated glomerular filtration rate. Evolocumab efficacy was tested using a Cox proportional hazards model. Results: Aortic stenosis events occurred in 63 patients (48 men [76%]; mean [SD] age, 69 [9] years) over a median of 2.2 years. Elevated Lp(a) concentration was associated with higher rates of AS events (adjusted hazard ratio [aHR], 1.55 [95% CI, 1.17-2.05] per SD; P = .002), including aortic valve replacement (aHR, 2.22 [95% CI, 1.38-3.58] per SD; P = .001), after multivariable adjustment. The corrected LDL-C concentration was not significantly associated with AS events (aHR, 1.23 [95% CI, 0.93-1.61] per SD; P = .14). The overall HR for AS events with evolocumab was 0.66 (95% CI, 0.40-1.09), with no apparent association in the first year (HR, 1.09 [95% CI, 0.48-2.47]) but an HR of 0.48 (95% CI, 0.25-0.93) after the first year of treatment. Conclusions and Relevance: In this exploratory analysis of the FOURIER trial, higher Lp(a) levels, but not Lp(a)-corrected LDL-C levels, were associated with a higher risk of subsequent AS events, including aortic valve replacement. Long-term therapy with evolocumab may reduce AS events, and this raises the possibility that specific pharmacologic lipid-lowering therapy could offer a means to prevent or slow the progression of AS. These exploratory findings merit further investigation with a dedicated randomized clinical trial. Trial Registration: ClinicalTrials.gov Identifier: NCT01764633.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Exploratory analyses suggest that long-term treatment with evolocumab may reduce the risk of aortic valve stenosis events.
“Exploratory analyses suggest that long-term treatment with evolocumab may reduce the risk of aortic valve stenosis events [53].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works
Self-citationClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · see citing works
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644 · see citing works
Self-citationA Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146 · see citing works
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008 · see citing works
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984 · see citing works
Self-citationChan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815 · see citing works
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.057 · Cited by 572 · see citing works
Self-citationOxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.020 · Cited by 417 · see citing works
Zheng, K. H., Tsimikas, S., Pawade, T., Kroon, J., Jenkins, W. S. A., Doris, M. K., White, A. C., Timmers, N. K. L. M., Hjortnaes, J., Rogers, M. A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.070 · Cited by 353 · see citing works
Arsenault, B. J., Boekholdt, S. M., Dubé, M.-P., Rhéaume, É., Wareham, N. J., Khaw, K.-T., Sandhu, M. S., & Tardif, J.-C. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000400 · Cited by 315 · see citing works
Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176 · see citing works
Self-citationLangsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1206 · Cited by 136 · see citing works
Bossé, Y., Mathieu, P., & Pibarot, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.031 · Cited by 82 · see citing works
Mundal, L. J., Hovland, A., Igland, J., Veierød, M. B., Holven, K. B., Bogsrud, M. P., Tell, G. S., Leren, T. P., & Retterstøl, K. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3903 · Cited by 43 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lipoprotein(a) and its Significance in Cardiovascular Disease
Lau, F. D., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 370 · see citing works
Self-citationCalcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 319 · see citing works
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281 · see citing works
Electrocardiogram screening for aortic valve stenosis using artificial intelligence
Cohen-Shelly, M., Attia, Z. I., Friedman, P. A., Ito, S., Essayagh, B. A., Ko, W.-Y., Murphree, D. H., Michelena, H. I., Enriquez-Sarano, M., Carter, R. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab153 · Cited by 252 · see citing works
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 106 · see citing works
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
Perrot, N., Valerio, V., Moschetta, D., Boekholdt, S. M., Dina, C., Chen, H. Y., Abner, E., Martinsson, A., Manikpurage, H. D., Rigade, S., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.004 · Cited by 91 · see citing works
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 70 · see citing works
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 58 · see citing works
The future of valvular heart disease assessment and therapy
Sengupta, P. P., Kluin, J., Lee, S., Oh, J. K., & Smits, A. I. P. M. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02754-x · Cited by 55 · see citing works
Broeders, W., Bekkering, S., Messaoudi, S. E., Joosten, L. A. B., van Royen, N., & Riksen, N. P. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00935-6 · Cited by 55 · see citing works
de Isla, L. P., Watts, G. F., Rodrigo Alonso, K., Díaz-Díaz, J. L., Muñiz-Grijalvo, O., Zambón, D., Fuentes, F. J., de Andrés, R., Padró, T., López‐Miranda, J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1066 · Cited by 51 · see citing works
PCSK9 promotes arterial medial calcification
Lupo, M. G., Bressan, A., Donato, M., Canzano, P., Camera, M., Poggio, P., Greco, M. F., Garofalo, M., Martin, S. D., Panighel, G., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.015 · Cited by 45 · see citing works
Lipoprotein(a): Emerging insights and therapeutics
Kaur, G., Abdelrahman, K., Berman, A. N., Biery, D. W., Shiyovich, A., Huck, D. M., Garshick, M. S., Blankstein, R., & Weber, B. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100641 · Cited by 48 · see citing works
Calcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45 · see citing works
Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century
Bélanger, A. M., Akioyamen, L. E., Ruel, I. L., Hales, L., & Genest, J. J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac339 · Cited by 39 · see citing works
The Pathophysiologic Basis and Management of Calcific Aortic Valve Stenosis
Desai, M. Y., & D, E. B. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.049 · Cited by 42 · see citing works
AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease
Han, D., Zhou, T., Li, L., Ma, Y., Chen, S., Yang, C., Ma, N., Song, M., Zhang, S., Wu, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065213 · Cited by 38 · see citing works
The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications
Phua, K., Chew, N., Kong, W. K. F., Tan, R., Ye, L., & Poh, K. K. (2022) · Theranostics · doi:10.7150/thno.71813 · Cited by 39 · see citing works
Tănase, D. M., Valasciuc, E., Gosav, E. M., Floria, M., Costea, C. F., Dima, N., Tudorancea, I., Maranducă, M. A., & Șerban, I. L. (2022) · Cells · doi:10.3390/cells11172663 · Cited by 37 · see citing works
Atherosclerosis Calcification: Focus on Lipoproteins
Neels, J. G., Lefthériotis, G., & Chinetti, G. (2023) · Metabolites · doi:10.3390/metabo13030457 · Cited by 37 · see citing works
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Greco, M. F., Sirtori, C. R., Corsini, A., Владиславович, Е. М., Sampietro, T., & Ruscica, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072103 · Cited by 32 · see citing works
Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Hu, J., Lei, H. C., Liu, L., & Xu, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812368 · Cited by 28 · see citing works
Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Nsaibia, M. J., Devendran, A. S., Goubaa, E., Bouitbir, J., Capoulade, R., & Bouchareb, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123331 · Cited by 24 · see citing works
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., Censi, L. D., Algeri, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010170 · Cited by 26 · see citing works
Dyslipidemia and aortic valve disease
Mata, P., Rodrigo Alonso, K., de Isla, L. P., & Badimón, L. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000794 · Cited by 23 · see citing works
Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis
Shah, S. M., Shah, J., Lakey, S., Garg, P., & Ripley, D. P. (2023) · Open Heart · doi:10.1136/openhrt-2022-002244 · Cited by 27 · see citing works
Yoon, D., Choi, B., Kim, J.-E., Kim, E., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E., & Song, J. (2024) · BMC Medicine · doi:10.1186/s12916-024-03342-x · Cited by 20 · see citing works
Evangelista, A., Galián-Gay, L., Guala, A., Teixidó‐Turà, G., Calvo, F., Sevilla, T., Bermejo, J., Méndez, I., Sánchez, V., Carmona, J. M. R., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067537 · Cited by 19 · see citing works
Association of Lipoprotein(a) With Severe Degenerative Aortic Valve Stenosis
Kim, A., Ahn, J., Kang, D., Jun, T. J., Sun, B. J., Kim, H. J., Kim, J. B., Kim, D., Park, D., Kim, Y., et al. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.07.007 · Cited by 18 · see citing works
Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
Gao, F., Li, Y. P., Ma, X., Wang, Z. J., Shi, D. M., & Zhou, Y. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907662 · Cited by 16 · see citing works
Bouhamida, E., Morciano, G., Pedriali, G., Ramaccini, D., Tremoli, E., Giorgi, C., Pinton, P., & Patergnani, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311105 · Cited by 16 · see citing works
Aortic valvular stenosis: Novel therapeutic strategies
Natorska, J., Kopytek, M., & Undas, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13527 · Cited by 15 · see citing works
PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
Grejtáková, D., Boroňová, I., Bernasovská, J., & Bellosta, S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07599-5 · Cited by 15 · see citing works
Blood biomarkers in left-sided valvular heart disease
Coisne, A., Lancellotti, P., Côté, N., Ternacle, J., Hecht, S., Grapsa, J., Hahn, R. T., Clavel, M.-A. A., Vannan, M. A., Lindman, B. R., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf232 · Cited by 15 · see citing works
Parthymos, I., Kostapanos, M. S., Mikhailidis, D. P., & Florentin, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab052 · Cited by 15 · see citing works
Aortic Stenosis: New Insights in Diagnosis, Treatment, and Prevention
Ito, S., & Oh, J. K. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2022.0234 · Cited by 18 · see citing works
Costanzo, A. D., Indolfi, C., Franzone, A., Esposito, G., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914939 · Cited by 16 · see citing works
Drugs for Prevention and Treatment of Aortic Stenosis: How Close Are We?
Afshar, M. S., Yazdan-Ashoori, S., Engert, J. C., & Thanassoulis, G. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.02.017 · Cited by 14 · see citing works
Pathological Mechanism and Treatment of Calcified Aortic Stenosis
Chen, S., Kong, X., & Zhang, J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000510 · Cited by 12 · see citing works
Atherosclerosis, calcific aortic valve disease and mitral annular calcification: same or different?
Hafiane, A., Pisaturo, A., Favari, E., & Bortnick, A. E. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132741 · Cited by 14 · see citing works
Regulatory roles of PIWI-interacting RNAs in cardiovascular disease
Shivam, P., Ball, D., Cooley, A., Osi, I., Rayford, K. J., Gonzalez, S. B., Edwards, A. D., McIntosh, A. R., Devaughn, J., Pugh-Brown, J. P., et al. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00833.2024 · Cited by 12 · see citing works
Lipoprotein(a) and aortic valve stenosis: A casual or causal association?
Santangelo, G., Faggiano, A., Bernardi, N., Carugo, S., Giammanco, A., & Faggiano, P. M. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.015 · Cited by 13 · see citing works
PCSK9 and Calcific Aortic Valve Stenosis
Leopold, J. A. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.06.004 · Cited by 13 · see citing works
Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions
Lan, N. S. R., Khan, Z. U., & Watts, G. F. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000976 · Cited by 11 · see citing works
Marrero, N., Jha, K. K., Razavi, A. C., Boakye, E., Anchouche, K., Dzaye, O. D. A., Budoff, M. J., Tsai, M. Y., Shah, S. J., Rotter, J. I., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.016372 · Cited by 11 · see citing works
Wodaje, T., Littmann, K., Häbel, H., Bottai, M., Bäck, M., Parini, P., & Brinck, J. W. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.02.016 · Cited by 11 · see citing works
Lp(a) - an overlooked risk factor
Laffin, L. J., & Nissen, S. E. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.003 · Cited by 12 · see citing works
Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization
Xu, D., Lu, J., Yang, Y., Hu, W., Chen, J., Xue, J., Yang, S., Cao, N., Hu, H., Qian, N., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119110 · Cited by 10 · see citing works
Mohammadnia, N., Vestjens, L. T. W., Craig, N. J., Tijssen, J. G. P., Knol, R. J. J., Lazarenko, S. V., Duffels, M. G. J., Focks, J. J., Hemels, M. E. W., Oving, I., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.07.010 · Cited by 10 · see citing works
Zheng, Y., Li, Q., Yang, Y., Yang, J., Liu, Z., Ma, X., & Wang, Z. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042112 · Cited by 11 · see citing works
The current landscape of lipoprotein(a) in calcific aortic valvular disease
Hsieh, G., Rizk, T., Berman, A. N., Biery, D. W., & Blankstein, R. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000901 · Cited by 10 · see citing works
Towards Personalized Therapy of Aortic Stenosis
Mazur, P. K., Kopytek, M., Ząbczyk, M., Undas, A., & Natorska, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121292 · Cited by 10 · see citing works
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.07.008 · Cited by 9 · see citing works
Lp(a) and thromboembolism: current state of knowledge and unsolved issues
Konieczyńska, M., Natorska, J., Ząbczyk, M., & Undas, A. (2024) · Archives of Medical Science · doi:10.5114/aoms/197357 · Cited by 9 · see citing works
Khan, M. I., Zahir, R. S., Dominguez, A. C., & Romeo, F. J. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101543 · Cited by 8 · see citing works
Navigating the Landscape of Translational Medicine of Calcific Aortic Valve Disease
Qian, X., Xu, L., Geng, B., Li, F., & Dong, N. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.01.014 · Cited by 8 · see citing works
Quarta, S., Santarpino, G., Carluccio, M. A., Calabriso, N., Maffia, M., Siculella, L., Damiano, F., Madonna, R., & Massaro, M. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107210 · Cited by 10 · see citing works
Aortic valve stenosis: the long and winding road
Kronenberg, F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1069 · Cited by 9 · see citing works
Nie, H., Zhao, W., Wang, Q., & Zhou, W. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf001 · Cited by 7 · see citing works
Myasoedova, V. A., Franchi, M., Giorgi, D. D., Bonomi, A., Valerio, V., Pirola, S., Andreani, N., Rusconi, V., Bertolini, F., Massaiu, I., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107737 · Cited by 9 · see citing works
Aortic valve stenosis: drivers of disease progression and drug targets for therapeutic opportunities
Pinto, G., & Fragasso, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2118576 · Cited by 7 · see citing works
Fauvel, C., Coisne, A., Capoulade, R., Bourg, C., Diakov, C., Ribeyrolles, S., Jouan, J., Folliguet, T. A., Kibler, M., Dreyfus, J., et al. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.06.004 · Cited by 7 · see citing works
Stroke and Noninfective Native Valvular Disease
Mayfield, J. J., & Otto, C. M. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01855-0 · Cited by 7 · see citing works
Fang, S., Deng, C., & Zhao, R. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44003 · Cited by 6 · see citing works
Profiling Genome-Wide DNA Methylation Patterns in Human Aortic and Mitral Valves
Halawa, S., Latif, N., Tseng, Y., Ibrahim, A. M., Chester, A. H., Moustafa, A., Aguib, Y., & Yacoub, M. H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.840647 · Cited by 6 · see citing works
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.03.002 · Cited by 6 · see citing works
Guo, Z., Xiong, Z., He, L., Zhang, S., Xu, X., Chen, G., Xie, M., Zhang, W., Hui, Z., Li, J., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02579-x · Cited by 6 · see citing works
Association of lipoprotein(a) and LPA gene with calcific aortic valve disease
Yu, X.-Y., Fu, Z.-A., Yu, M., & Shi, Y.-B. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-03071-8 · Cited by 7 · see citing works
Agstam, S., Agarwal, T., Gupta, A., & Bansal, S. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.01.017 · Cited by 6 · see citing works
Kapelouzou, A., Geronikolou, S. A., Lidoriki, I., Kontogiannis, C., Kaklamanis, L., Tsourelis, L., & Cokkinos, D. V. (2023) · Biology · doi:10.3390/biology12030347 · Cited by 6 · see citing works
Aortic Stenosis: Diagnosis, Molecular Mechanisms and Therapeutic Strategies—A Comprehensive Review
Banceu, C. M., Cristutiu, D., Gurzu, S., Harpa, M. M., Banceu, D. M., & Suciu, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144949 · Cited by 8 · see citing works
The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
Razavi, A. C., & Shapiro, M. D. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101314 · Cited by 5 · see citing works
Current Management and Therapy of Severe Aortic Stenosis and Future Perspective
Takeji, Y., Tada, H., Taniguchi, T., Sakata, K., Kitai, T., Shirai, S., & Takamura, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22023 · Cited by 5 · see citing works
Genetics of Calcific Aortic Stenosis: A Systematic Review
Vassiliou, V. S., Johnson, N. J., Langlands, K., & Tsampasian, V. (2024) · Genes · doi:10.3390/genes15101309 · Cited by 5 · see citing works
SU, H., Guo, X., Li, Q., Yuan, X., Wu, X., Zhao, Z., Kan, Y., Yang, Y., Fu, Z., Qi, Z., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1744830 · Cited by 4 · see citing works
Lipoprotein (a) Distribution in Aortic Stenosis Patients
Durr, M.-R. R., Burwash, I. G., LAU, L. S. W., Alfraidi, H., Mulloy, A. J., Tavoosi, A., Arangalage, D., Chan, V., Lakhani, M., Aljamaan, A., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101662 · Cited by 4 · see citing works
Modern Lipid Management: A Literature Review
Malik, J., Shabeer, H., Ishaq, U., Chauhan, H., & Akhtar, H. F. (2020) · Cureus · doi:10.7759/cureus.9375 · Cited by 4 · see citing works
Lipoprotein(a)—When to Screen and How to Treat
Patel, N., Mittal, N., Choubdar, P. A., & Taub, P. R. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00698-8 · Cited by 4 · see citing works
Preventing Aortic Stenosis by Changing the Way We Think About an Old Disease
Thanassoulis, G. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0722 · Cited by 4 · see citing works
Surma, S., Zembala, M. O., Okopień, B., & Banach, M. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200297 · Cited by 3 · see citing works
Theodoropoulou, T., Mourouzis, I. S., Katsaouni, A., Pantos, C. I., Tsioufis, K. P., & Toutouzas, K. P. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177985 · Cited by 4 · see citing works
Unraveling the Link Between Aortic Stenosis and Atherosclerosis: What Have We Learned?
Cinezan, C., Rus, C. B., & Ilias, I. T. (2025) · Medicina · doi:10.3390/medicina61081375 · Cited by 4 · see citing works
Valvular heart failure: evolving pharmacological approaches
Docherty, K. F., Otto, C. M., & McMurray, J. J. V. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1079 · Cited by 3 · see citing works
Hemelrijk, K. I., Delewi, R., Mehran, R., & Boekholdt, S. M. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120731 · Cited by 5 · see citing works
Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis
Burdeynaya, A. L., Afanasieva, O. I., Владиславович, Е. М., Александровна, К. Е., Saidova, M. A., & Pokrovsky, S. N. (2023) · Diseases · doi:10.3390/diseases11010043 · Cited by 3 · see citing works
Moderate Aortic Stenosis—Advanced Imaging, Risk Assessment, and Treatment Strategies
Adrichem, R., van den Dorpel, M. M. P., Hirsch, A., Geleijnse, M. L., Budde, R. P. J., & Mieghem, N. M. V. (2024) · Structural Heart · doi:10.1016/j.shj.2023.100279 · Cited by 3 · see citing works
Masson, W. M., Lobo, M., Barbagelata, L., Bagnati, R. P., OBERTI, P. F., Falconi, M. L., Krauss, J. G., PARCERISA, F., & Pizarro, R. (2022) · Revista Argentina de Cardiología · doi:10.7775/rac.v90.i3.20516 · Cited by 3 · see citing works
Capoulade, R., & Cariou, B. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.009 · Cited by 3 · see citing works
Hou, Y., Zhao, J., Xu, W., Chen, L., Yang, J., Wang, Z., & Si, K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34089 · Cited by 2 · see citing works
Association between evolocumab use and slow progression of aortic valve stenosis
Terasaka, K., Gohbara, M., Abe, T., Yoshii, T., Hanajima, Y., Kirigaya, J., Horii, M., Kikuchi, S., Nakahashi, H., Matsushita, K., et al. (2024) · Heart and Vessels · doi:10.1007/s00380-024-02386-6 · Cited by 2 · see citing works
Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory
Velilla, T. A., Fernández‐Prendes, C., Amigó, N., Calmarza, P., Anguila, S. C., Estébanez, B. C., Castro, M. J. C., Ceacero-Marín, D., Martínez, I. G., Palencia, M. M., et al. (2025) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2025-0034 · Cited by 2 · see citing works
Sampath-Kumar, R., Padilla, E., Wilkinson, M. J., Barba, D. T., Aramburo, N., Mahmud, E., Ben‐Yehuda, O., & Taub, P. R. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102247 · Cited by 2 · see citing works
Schmidt, L. E., Burnap, S. A., Singh, B., Takov, K., Losdat, S., Schrutka, L., Galli, L., Theofilatos, K., Otto, G., Hengstenberg, C., et al. (2026) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005345 · Cited by 2 · see citing works
Bencivenga, L., Sepe, I., Palaia, M. E., Komici, K., Corbi, G., Puzone, B., Arcopinto, M., Cittadini, A., Ferrara, N., Femminella, G. D., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa053 · Cited by 2 · see citing works
Loutradis, C., Sarafidis, P. A., Ortíz, A., & Ferro, C. J. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01242-w · Cited by 2 · see citing works
Akgün, D. E. (2024) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2023.3695 · Cited by 2 · see citing works
Clinical Update on the Intersection of Lipoprotein(a) and Calcific Valve Disease
Ashley, S. C., Kachhy, E., Brown, K. A., Prescott, M. E., Kelsey, M. D., McGarrah, R. W., Pagidipati, N. J., & Shah, N. P. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00765-w · Cited by 1 · see citing works
Lipoprotein(a) and risk of recurrent atrial fibrillation after pulsed field ablation
Zuin, M., Canovi, L., Vitali, F., Balla, C., Malagù, M., & Bertini, M. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001787 · Cited by 1 · see citing works
PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification
Zhang, X., Hao, Y., Han, D., Jin, X., Shang, X., Zhang, L., Gan, Z., Ye, W., Wang, S., Li, X., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.078830 · Cited by 1 · see citing works
Courtney, W., Walker, J. A., Dorai-Raj, A., Arnous, S., O’Connor, C. T., Playford, D. A., Ihdayhid, A. R., Schultz, C. J., Hillis, G. S., & Kiernan, T. J. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2652411 · Cited by 1 · see citing works
- Authors
- Bergmark, B. A., O’Donoghue, M. L., Murphy, S. A., Kuder, J. F., Ezhov, M. V., Ceška, R., Gouni-Berthold, I., Jensen, H. K., Tokgozoglu, S. L., Mach, F., Huber, K., Gaciong, Z., Lewis, B. S., Schiele, F., Jukema, J. W., Pedersen, T. R., Giugliano, R. P., & Sabatine, M. S.
- Affiliations
- Brigham and Women's Hospital (US)
- National Medical Research Center of Cardiology, Moscow, Russia
- Third Internal Medicine Clinic, Center for Preventive Cardiology, University General Hospital, First Medical Faculty, Charles University, Prague, Czech Republic
- Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany
- Aarhus University (DK)
- Hacettepe University (TR)
- University Hospital of Geneva (CH)
- Sigmund Freud Privatuniversität Wien (AT)
- Medical University of Warsaw (PL)
- Technion – Israel Institute of Technology (IL)
- University Hospital Center Besançon, Besançon, France
- Leiden University Medical Center (NL)
- Oslo University Hospital (NO)
- Corresponding author
- Bergmark, Brian A.
- ORCID
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-06-01
- Volume
- 5
- Issue
- 6
- Pages
- 709
- ISSN
- 2380-6583 (ISSN-L)
- PMC
- PMC7301224
- OpenAlex
- W3018871408
- Cited by
- 137
- References
- 15
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 29 · 2023: 18 · 2022: 20 · 2021: 12 · 2020: 13
- FWCI
- 14.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Cardiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc-nd)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Brigham and Women's Hospital
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- Intarcia Therapeutics
- Amarin Corporation
- Medicines Company
- IFM Therapeutics
- Kowa Company
- Mylan
- Bayer HealthCare
- Daiichi-Sankyo
- Eisai
- Novo Nordisk (NNF18OC0031258)
- Novo Nordisk Fonden (NNF18OC0031258)
- Servier
- Esperion Therapeutics
- Netherlands Heart Institute
- Janssen Research and Development
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- aortic stenosis, evolocumab, PCSK9 inhibition, lipoprotein(a), LDL cholesterol, aortic valve replacement, atherosclerotic cardiovascular disease, FOURIER trial, disease-modifying therapy, statin therapy, cardiovascular risk factors, aortic valve replacement timing, aortic stenosis progression
- MeSH terms
- PCSK9 Inhibitors, Anticholesteremic Agents, Aortic Valve Stenosis, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Treatment Outcome, Subtilisin, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
